SciVision Biotech Inc
TWSE:1786

Watchlist Manager
SciVision Biotech Inc Logo
SciVision Biotech Inc
TWSE:1786
Watchlist
Price: 90.7 TWD -1.41% Market Closed
Market Cap: 6.4B TWD
Have any thoughts about
SciVision Biotech Inc?
Write Note

SciVision Biotech Inc
Income from Continuing Operations

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
TTM
|

SciVision Biotech Inc
Income from Continuing Operations Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Income from Continuing Operations CAGR 3Y CAGR 5Y CAGR 10Y
SciVision Biotech Inc
TWSE:1786
Income from Continuing Operations
NT$216m
CAGR 3-Years
25%
CAGR 5-Years
14%
CAGR 10-Years
43%
M
Medtecs International Corporation Ltd
SGX:546
Income from Continuing Operations
-$21.4m
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
V
Visco Vision Inc
TWSE:6782
Income from Continuing Operations
NT$294.6m
CAGR 3-Years
32%
CAGR 5-Years
8%
CAGR 10-Years
N/A
P
Pegavision Corp
TWSE:6491
Income from Continuing Operations
NT$2B
CAGR 3-Years
25%
CAGR 5-Years
86%
CAGR 10-Years
N/A
OK Biotech Co Ltd
TWSE:4155
Income from Continuing Operations
NT$50.7m
CAGR 3-Years
-14%
CAGR 5-Years
-18%
CAGR 10-Years
N/A
No Stocks Found

SciVision Biotech Inc
Glance View

Market Cap
6.4B TWD
Industry
Health Care

SciVision Biotech, Inc. engages in the research, development, and production of hyaluronic acid medical products. The company is headquartered in Kaohsiung, Kaohsiung. The company went IPO on 2010-12-29. The firm primarily provides subcutaneous fillers for plastic surgery facial injection, joint cavity injections for orthopedics use, as well as hyaluronic acid raw materials, among others. The firm is also involved in deoxyribonucleic acid (DNA) identification, detection, sequencing and application, as well as the manufacturing of care products and foods. The firm operates its business in the Americas, Europe, Asia, Middle East and Africa.

Intrinsic Value
178.54 TWD
Undervaluation 49%
Intrinsic Value
Price

See Also

What is SciVision Biotech Inc's Income from Continuing Operations?
Income from Continuing Operations
216m TWD

Based on the financial report for Sep 30, 2024, SciVision Biotech Inc's Income from Continuing Operations amounts to 216m TWD.

What is SciVision Biotech Inc's Income from Continuing Operations growth rate?
Income from Continuing Operations CAGR 10Y
43%

Over the last year, the Income from Continuing Operations growth was 28%. The average annual Income from Continuing Operations growth rates for SciVision Biotech Inc have been 25% over the past three years , 14% over the past five years , and 43% over the past ten years .

Back to Top